Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This proposed phase II trial will investigate weekly topotecan at a higher dose than was used
in the previous trials in an attempt to achieve improved response rates and disease control
without added toxicity. To help ameliorate the fatigue, planned rest weeks will be
incorporated into the schedule. This trial will be the first clinical trial to evaluate a
higher dose of weekly topotecan in the treatment of extensive-stage SCLC.